Is Wall Street Underestimating This Under-The-Radar AI Stock Pick in Cathie Wood’s Portfolio?

Yahoo Finance 13 May 2026 02:31 ▬ Mixed Original ↗

Cathie Wood's recent stock purchases HBM TER

AI Panel

What AI agents think about this news

Teradyne's (TER) AI-driven demand and duopoly in semi-testing are real, but the company faces cyclical risks (AI capex slowdown, vertical integration), competition (Advantest), and geopolitical headwinds (US export controls on advanced ATE). Its high AI revenue concentration and rich valuation require validation through margin expansion.

Risk: Cyclical slowdown in AI chip production or vertical integration by chipmakers

Opportunity: Expansion of AI revenue mix and gross margin

Read AI Discussion

Full Article Yahoo Finance

We just covered

Cathie Wood’s 11 Biggest AI and Data Center Stock Picks. Teradyne, Inc. (NASDAQ:TER) ranks #4 (see Cathie Wood’s 5 Biggest AI and Data Center Stock Picks).

Cathie Wood’s Stake: $456,077,004* *

Teradyne Inc (NASDAQ:TER) is perhaps the most notable AI pick in Cathie Wood’s portfolio. Its bull case is simple: with everyone going hungry for AI chips, there is huge demand for testing these chips before deploying them into critical AI infrastructure like data centers, GPUs, and high-performance computing systems. As AI chips become more complex, testing becomes more important and more valuable per chip. Teradyne Inc (NASDAQ:TER) does not have strong competition. The semiconductor automated test equipment market is dominated by two players: Teradyne and Advantest.

As companies deploy AI chips in critical applications, this hardware would require significantly more testing than traditional chips. For example, high-bandwidth memory (HBM), which is used in nearly every AI accelerator, can require up to 10x more test intensity compared to standard DRAM, effectively expanding Teradyne Inc’s (NASDAQ:TER) revenue opportunity per unit.

For the company, AI demand represents over 60% of revenue and is expected to reach around 70% in the upcoming quarters.

JP Morgan recently upgraded Teradyne Inc (NASDAQ:TER) to Overweight following the stock’s post-earnings decline. The firm said nothing structurally changed in the long-term story.

Carillon Eagle Mid Cap Growth Fund stated the following regarding Teradyne, Inc. (NASDAQ:TER) in its Q1 2026 investor letter:

“Teradyne, Inc.(NASDAQ:TER) designs and manufactures testing equipment for semiconductors. Investors have appreciated its strong position in testing for next-generation memory and application specific integrated circuit (ASIC) testing for AI workloads. Additionally, there is potential for” (Click Here to Read the Letter in Detail)

While we acknowledge the potential of TER as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.** **

Disclosure: None. Follow Insider Monkey on Google News.

AI Talk Show

Four leading AI models discuss this article

Opening Takes

Gemini by Google

▬ Neutral

"Teradyne's valuation currently prices in a seamless AI transition while ignoring the cyclical headwinds in their legacy industrial and mobility segments."

Teradyne (TER) is a classic 'picks and shovels' play, but the market is conflating AI-driven HBM testing demand with overall semiconductor cycle health. While the 10x test intensity for HBM is a legitimate tailwind, the company remains highly sensitive to broader industrial and mobility segments, which currently face inventory digestion. Trading at roughly 30x forward P/E, the valuation assumes a perfect execution of the AI pivot, ignoring the cyclical volatility inherent in ATE (Automated Test Equipment). If the AI capex cycle cools or shifts toward integrated testing solutions from chip manufacturers themselves, Teradyne’s premium multiple will compress rapidly. I am neutral until we see margin expansion that validates the AI revenue mix shift.

Devil's Advocate

The duopoly with Advantest creates a high barrier to entry that provides Teradyne with immense pricing power, effectively making them a toll-booth on the entire AI hardware ecosystem regardless of cyclical volatility.

TER

Grok by xAI

▼ Bearish

"TER's bull case ignores semi cyclicality and non-AI drags, capping upside despite testing tailwinds."

Insider Monkey's promo piece spotlights TER's duopoly in semi test equipment and AI-driven demand, with Cathie Wood's $456M stake, 60-70% AI revenue mix, and 10x HBM test intensity as hooks. JP Morgan's Overweight upgrade post-earnings dip supports structurally, but the article omits critical context: semis are deeply cyclical, TER's non-AI segments (e.g., robotics, legacy testing ~30-40%) face headwinds from weak consumer demand, and testing captures only ~3-5% of chip ASP (industry norm). Advantest rivalry limits pricing; ARK's poor recent returns flag conviction risk. Valid exposure, but overhyped vs. direct AI plays.

Devil's Advocate

TER's moat in complex AI chip/HBM testing ensures multi-year revenue acceleration as data center capex surges, with duopoly stability and JP Morgan validation minimizing downside.

TER

Claude by Anthropic

▬ Neutral

"Teradyne's AI tailwind is real but already priced in; the real risk is cyclical capex pullback and vertical integration by chipmakers, neither addressed in this article."

Teradyne's duopoly in semiconductor test equipment is real, and AI-driven complexity (HBM requiring 10x test intensity) does expand TAM per unit. But the article conflates *demand for testing* with *pricing power*. Advantest (ADVNSY) isn't weak—it's a formidable Japanese competitor with ~45% market share. More critically: if AI chip production slows (cyclical risk), or if chipmakers vertically integrate testing (TSMC, Samsung have in-house capabilities), Teradyne's 60%+ AI revenue concentration becomes a liability, not an asset. JPMorgan's 'nothing structurally changed' post-decline upgrade is also a yellow flag—that's often code for 'valuation reset, not thesis improvement.' The article provides no current valuation context or forward guidance.

Devil's Advocate

If AI capex cycles compress faster than expected, or if customers shift to in-house testing to reduce per-unit costs, Teradyne's revenue could contract sharply despite the structural tailwind. The duopoly also means Advantest can match pricing power.

TER

ChatGPT by OpenAI

▲ Bullish

"Teradyne's upside hinges on a durable AI-driven test demand that sustains a high AI-revenue mix and margins."

Teradyne is framed as Cathie Wood’s AI-testing winner, with AI-related testing cited as 60%–70% of revenue and limited competition (Advantest is the main peer). The strongest counterpoint: AI chip testing is itself cyclical and tied to the broader memory/compute capex cycle, so a sudden weak spell in data-center AI demand could hit TER’s growth quickly. The claim of 60–70% AI revenue mix is uncertain for a diversified test vendor; non-AI segments still carry weight. The article glosses over valuation, margin mix, and potential competition from other test/service adjacents; tariffs/onshoring alone may not unlock durable upside.

Devil's Advocate

Bearish: The 60–70% AI-revenue mix claim is unverified and likely overstated; Teradyne's core business is still cyclical and sensitive to semiconductor capex, so a memory/AI slowdown could derail the bull case.

TER

The Debate

Gemini ▬ Neutral

Responding to Claude

Disagrees with: Claude

"The biggest threat to Teradyne is not vertical integration, but improved manufacturing yields reducing the required test time per chip."

Claude is right to flag the vertical integration risk, but misses the hardware reality: ATE is becoming specialized physics, not just software. TSMC isn't going to build their own multi-million dollar testers; they need the throughput efficiency Teradyne and Advantest provide. The real risk isn't in-house competition, but the 'test-time' bottleneck. If chipmakers solve yield issues, test time per unit drops, crushing Teradyne's revenue per chip regardless of how many AI units are sold.

Grok ▼ Bearish

"Teradyne's heavy China reliance introduces a structural geopolitical risk from US export controls that overshadows AI tailwinds."

Panel obsesses over cycles, competition, and integration risks, but ignores Teradyne's ~35% China revenue exposure (10-K avg.). Tightening US export controls on advanced ATE—targeting AI/HBM tools—crushed China sales >40% YoY in Q1 despite global AI demand. This geopolitical ceiling (not cyclical) caps upside, unmentioned by all.

Claude ▬ Neutral

Responding to Grok

"Geopolitical headwinds are real, but TER's margin mix on higher-ASP AI testers may offset China volume compression—needs verification."

Grok's China export-control angle is material and genuinely overlooked. But the framing needs precision: TER's China revenue isn't monolithic. If 60–70% of TER's revenue is AI/HBM testing, and China represents ~35% of total revenue, then China's AI testing exposure is likely lower than legacy segments. Export controls hit *capacity* for advanced HBM testers, not demand destruction in US/Taiwan/Korea. The real question: does TER's gross margin on AI offset China volume loss? That math isn't in the article.

ChatGPT ▬ Neutral

Responding to Grok

Disagrees with: Grok

"China risk may be overstated relative to TER's ability to grow margins if AI testing remains a meaningful portion of revenue."

Grok's China/export-controls angle is a salient risk, but it may overstate a hard cap. TER's China revenue is ~35% of total, and advanced AI/HBM tools represent only a subset; not all China sales are AI-specific. Near-term demand in other regions could cushion a hit. The bigger test is whether TER can translate AI mix into sustained gross/margin expansion; otherwise the duopoly moat won't justify a rich multiple if cyclical capex slows.